Journal of Cardiac Failure
Volume 16, Issue 9 , Pages 714-719 , September 2010

The Effects of Adenosine A1 Receptor Antagonism in Patients With Acute Decompensated Heart Failure and Worsening Renal Function: The REACH UP Study

  • Stephen S. Gottlieb, MD

      Affiliations

    • University of Maryland, Baltimore, MD
    • Corresponding Author InformationReprint requests: Stephen Gottlieb, MD, University of Maryland School of Medicine, 22 S. Greene St, Baltimore, MD 21209. Tel: (410) 328-8788; Fax: (410) 328-1048.
    • ,
  • Michael M. Givertz, MD

      Affiliations

    • Brigham and Women's Hospital, Boston, MA
    • ,
  • Marco Metra, MD

      Affiliations

    • University of Brescia, Brescia, Italy
    • ,
  • Kevin Gergich, MA

      Affiliations

    • Merck & Co., Inc, Whitehouse Station, NJ
    • ,
  • Steven Bird, MS

      Affiliations

    • Merck & Co., Inc, Whitehouse Station, NJ
    • ,
  • Charlotte Jones-Burton, MD, MS

      Affiliations

    • Merck & Co., Inc, Whitehouse Station, NJ
    • ,
  • Barry Massie, MD

      Affiliations

    • University of California, San Francisco
    • ,
  • Gad Cotter, MD

      Affiliations

    • Momentum Research, Durham, NC
    • ,
  • Piotr Ponikowski, MD

      Affiliations

    • Military Hospital, Department of Health Sciences, Medical University, Wroclaw, Poland
    • ,
  • Beth Weatherley, PhD

      Affiliations

    • Momentum Research, Durham, NC
    • ,
  • Christopher O'Connor, MD

      Affiliations

    • Duke University Medical Center, Durham, NC
    • ,
  • Howard Dittrich, MD

      Affiliations

    • NovaCardia, Inc, San Diego, CA

Received 11 February 2010 ,Revised 16 April 2010 ,Accepted 21 April 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Funded by NovaCardia, Inc. As of September 2007, NovaCardia is a wholly owned subsidiary of Merck & Co, Inc. Based on the lack of a benefit on the predefined end points in the PROTECT trial, Merck has reported it will not pursue further development of rolofylline.

 All decisions regarding this manuscript were made by a guest editor.

 See page 719 for disclosure information.

PII: S1071-9164(10)00196-X

doi: 10.1016/j.cardfail.2010.04.006

Journal of Cardiac Failure
Volume 16, Issue 9 , Pages 714-719 , September 2010

Article Tools

* Image Usage & Resolution